Obesity Icon in white

Obesity

Explore facts and recommendations for pharmacological treatments for obesity.

pharmacotherapies
Filters

We are still gathering material for this library.

Please check again soon.

We're sorry

We didn't find any resources that match your selection.

Please adjust your filter(s) and try again.

pharmacotherapies
 
Obesity Video

Subcutaneous Semaglutide vs Placebo for Weight Management in Combination with IBT (STEP 3)

This video discusses STEP 3, which was a Phase 3a, 68-week, randomized, placebo-controlled, double-blind, multicenter trial conducted in 611 adult patients with obesity or overweight and at least 1 weight-related comorbidity in the US

Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
Obesity Video

Subcutaneous Semaglutide 2.4mg vs Subcutaneous Semaglutide 1.0mg and Placebo for Weight Management in Adults with Type 2 Diabetes (STEP 2)

This video discusses STEP 2, which was a Phase 3a, 68-week, randomized, placebo-controlled, double-dummy, double-blind, multicenter, multinational trial conducted in 1210 adult patients with obesity or overweight and type 2 diabetes.

Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
Obesity Video

Semaglutide injection Mode of Action in Obesity

This video discusses the mechanism of action of the subcutaneous semaglutide injection indicated for Obesity.

Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
Preview
Obesity PDF

Current Recommendations for Weight-Loss Medications as Part of Obesity Management (IME content)

Snapshot of why medication is a powerful tool in obesity management.

Download
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
Obesity Video

Subcutaneous Semaglutide vs Placebo for Weight Management in Adults (STEP 1)

This video discusses the STEP 1 trial, which was a phase 3a, 68-week, randomized, placebo-controlled, double-blind, multinational trial conducted in 1961 adult patients with obesity, or overweight with at least 1 weight-related comorbidity.

Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
Preview
Obesity PDF

STEP 1 Clinical Trial: Weight Management with Semaglutide Injection

Results of a 68-week trial comparing weight loss while receiving semaglutide injection or placebo in 1961 adults with obesity or overweight.

Download
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
Preview
Obesity PDF

STEP 2 Clinical Trial: Weight Management with Semaglutide Injection in Adults with Type 2 Diabetes

Findings of a 68-week trial comparing semaglutide injection 2.4mg vs placebo vs semaglutide injection 1.0 mg in 1210 adults with overweight or obesity and Type 2 diabetes.

Download
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
Preview
Obesity PDF

STEP 3 Clinical Trial: Weight Management with Semaglutide Injection and Intensive Behavioral Therapy (IBT)

Outcomes of a 68-week trial comparing semaglutide injection vs placebo in combination with IBT in 611 adults with obesity or overweight and at least 1 weight-related comorbidity.

Download
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close

Obesity

congress materials
View Resources

Obesity

disease education
View Resources
continuing education icon

Continuing Education

Find accredited opportunities in obesity education.

Explore CE Activities

Looking for additional resources?
Explore other libraries or search the Exchange.

Novo Nordisk® Scientific Exchange logo

Scientific Exchange is a trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to www.novonordiskpro.com.

This medical content was developed independently by a third party via an educational grant. This material is copyright protected and is provided here with permission for educational and informational purposes only and is not certified for continuing education credits.

Continue

You are now leaving the Novo Nordisk Scientific Exchange website.

Our Privacy Policy applies only to this and other websites maintained by Novo Nordisk. Links are provided as a public service and for informational purposes only. No endorsement is made or implied. Click "Continue" to leave this site.

Continue

GATED INTERSTITAL  

You are now leaving the Novo Nordisk Scientific Exchange website.

Our Privacy Policy applies only to this and other websites maintained by Novo Nordisk. Links are provided as a public service and for informational purposes only. No endorsement is made or implied. Click "Continue" to leave this site.

ACCESS DENIED

Our Privacy Policy applies only to this and other websites maintained by Novo Nordisk. Links are provided as a public service and for informational purposes only. No endorsement is made or implied. Click "Continue" to leave this site.